4 research outputs found
Mesenchymal Stem Cells in Organ Transplantation: Immunomodulatory properties of mesenchymal stem cells for application in organ transplantation
Kidney transplantation is the only effective treatment for patients with end-stage renal disease.
Transplantation of a donor organ, however, leads to recognition of the foreign donor antigens by the
recipient’s immune system, resulting in rejection of the graft. In addition, ischemia-reperfusion injury
leads to the initiation of immune responses. To prevent graft rejection, transplant recipients need to
use life-long immunosuppressive medication. These drugs, however, can lead to serious acute and
chronic side effects, such as infections, nephrotoxicity, cardiovascular disease and malignancies 1.
As an alternative, cellular therapies may be considered. One of the candidates is the mesenchymal
stem cell (MSC). Mesenchymal stem cells have tissue regenerative and immunosuppressive
properties 2-4. These properties make them promising as cellular therapy for tissue regeneration and
treatment of immunological disease. In solid organ transplantation, MSC may repair graft injury
and may reduce anti-donor reactivity, thereby improving graft function and alleviating the need for
immunosuppressive drugs after transplantation. Despite recent clinical trials investigating the use
of MSC in treating immune-mediated disease, such as therapy resistant graft-versus-host disease
(GVHD) and inflammatory bowel disease, the applicability of MSC in solid organ transplantation
is still unknown. The present thesis discusses the immunomodulatory properties of MSC and their
potential to improve the outcome of solid organ transplantation
Diagnostic value of urinary dysmorphic erythrocytes in clinical practice
Background: In clinical practice, discriminating between glomerular and nonglomerular causes of hematuria is often difficult. Dysmorphic red blood cells (dRBC) in the urinary sediment are claimed to be effective, but the cutoff points in the literature vary. This follow-up study aimed to determine the diagnostic value of dRBC. Methods: We investigated 134 hematuria patients in the departments of nephrology and urology. To diagnose the origin of hematuria, urological and/or nephrological examination was performed and the %dRBC identified by microscopy. Follow-up was performed after 3.5 years. Results: The cause of hematuria was proven in 68 patients (35% glomerular; 65% nonglomerular). Patients with glomerular disease had significantly more albuminuria and dRBC than patients with nonglomerular disease, but the %dRBC ranged from 1 to 50% and no optimal cutoff could be identified. Logistic regression analysis showed that %dRBC had a predicted probability to diagnose glomerular disease of 77.9% (area under the curve, AUC, 0.85). When %dRBC was combined with other risk factors such as serum creatinine, sex, age, dipstick erythrocyte or proteinuria score and number of casts, the predictive probability increased to 90.6% (AUC 0.97). Follow-up of the included patients showed no benefit of dRBC to identify patients at risk for glomerular disease. Conclusions: The diagnostic value of routinely collected urinary dRBC to diagnose glomerular disease in patients presenting with hematuria is modest. However, including dRBC with other variables, such as age and erythrocyte score on dipstick testing may increase the sensitivity, but needs to be confirmed in another, preferably larger, population. Copyrigh
Hypokalaemia and subsequent hyperkalaemia in hospitalized patients
Background. The objective was to study the epidemiology of hypokalaemia [serum potassium concentration (SK) <3.5 mmol/l] in a general hospital population, specifically focusing on how often and why patients develop subsequent hyperkalaemia (SK<5.0 mmol/l). Methods. In a 3-month hospital-wide study we analysed factors contributing to hypokalaemia and subsequent hyperkalaemia. Results. From 1178 patients in whom SKwas measured, 140 patients (12%) with hypokalaemia were identified (SK3.0 ± 0.3 mmol/l). One hundred patients (71%) had hospital-acquired hypokalaemia. Common causes of hypokalaemia included gastrointestinal losses (67%), diuretics (36%) and haematological malignancies (9%). In 104 patients (74%), hypokalaemia was multifactorial. Hypokalaemia frequently coexisted with hyponatraemia (24%) and, when measured, hypomagnesaemia (61%). Twenty-three patients (16%) developed hyperkalaemia (highest SK5.7 ± 0.7 mmol/l) following hypokalaemia. In these patients, potassium suppletion was not more common (70 vs 59%, P = 0.5), but when potassium wa
Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells
There is emerging interest in the application of mesenchymal stem cells (MSC) for the prevention and treatment of autoimmune diseases, graft-versus-host disease and allograft rejection. It is, however, unknown how inflammatory conditions affect phenotype and function of MSC. Adipose tissue-derived mesenchymal stem cells (ASC) were cultured with alloactivated peripheral blood mononuclear cells (PBMC) (mixed lymphocyte reaction: MLR), with proinflammatory cytokines [interferon (IFN)-γ, tumour necrosis factor (TNF)-α and interleukin (IL)-6] or under control conditions, and their full genome expression and function examined. Proinflammatory cytokines mainly increased indoleamine-2,3-dioxygenase expression, whereas ASC cultured with MLR showed increased expression of COX-2, involved in prostaglandin E 2 production. Both conditions had a stimulatory, but differential, effect on the expression of proinflammatory cytokines and chemokines, while the expression of fibrotic factors was decreased only in response to proinflam- matory cytokines. Functional analysis demonstrated that inflammatory conditions affected morphology and proliferation of ASC, while their differentiation capacity and production of trophic factors was unaffected. The immunosuppressive capacity of ASC was enhanced strongly under inflammatory c